Clinical Trials Browser

Unknown × Breast Neoplasms × Letrozole × Clear all

NCT03906669 2023-11-22

WinPro

Phase 2 Unknown

Breast Neoplasms

NCT05800197 2023-04-06

NEMO

Breast Neoplasms

NCT00412022 2023-03-24

HOBOE

Phase 3 Unknown

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

Breast Neoplasms

NCT04942899 2023-03-01

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown

Breast Neoplasms

NCT05512416 2022-08-23

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03913234 2022-05-10

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Phase 1/2 Unknown

Breast Neoplasms

NCT04407988 2021-10-13

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04047758 2021-07-20

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Breast Neoplasms

NCT04792840 2021-03-11

Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer

Breast Neoplasms

NCT04666805 2020-12-14

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT01758146 2020-03-04

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

Phase 3 Unknown

Breast Neoplasms, Obesity

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Phase 3 Unknown

Breast Neoplasms

NCT04095390 2019-09-19

INPHASE

Phase 2 Unknown

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Phase 2 Unknown

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

Phase 2 Unknown

Breast Neoplasms

NCT03507465 2018-04-25

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT03497702 2018-04-13

NeoChAI

Phase 2 Unknown

Breast Neoplasms

NCT02214004 2018-02-15

HERAKLES

Phase 2 Unknown

Breast Neoplasms

NCT02769104 2018-01-09

ACCN

Phase 3 Unknown

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

Phase 2 Unknown

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Phase 3 Unknown

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT01814449 2013-03-20

Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer

Hypoxia, Breast Neoplasms

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00902954 2009-05-15

LEANEX

Phase 3 Unknown

Breast Neoplasms